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Abstract
The adaptive cellular response to low oxygen tensions is mediated
by the hypoxia-inducible factors (HIFs), a family of heterodimeric
transcription factors composed of HIF-a and HIF-b subunits.
Prolonged HIF expression is a key contributor to cellular transfor-
mation, tumorigenesis and metastasis. As such, HIF degradation
under hypoxic conditions is an essential homeostatic and tumour-
suppressive mechanism. LIMD1 complexes with PHD2 and VHL in
physiological oxygen levels (normoxia) to facilitate proteasomal
degradation of the HIF-a subunit. Here, we identify LIMD1 as a
HIF-1 target gene, which mediates a previously uncharacterised,
negative regulatory feedback mechanism for hypoxic HIF-a degra-
dation by modulating PHD2-LIMD1-VHL complex formation.
Hypoxic induction of LIMD1 expression results in increased HIF-a
protein degradation, inhibiting HIF-1 target gene expression,
tumour growth and vascularisation. Furthermore, we report that
copy number variation at the LIMD1 locus occurs in 47.1% of lung
adenocarcinoma patients, correlates with enhanced expression of
a HIF target gene signature and is a negative prognostic indicator.
Taken together, our data open a new field of research into the
aetiology, diagnosis and prognosis of LIMD1-negative lung cancers.
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Introduction
The HIF family of transcription factors are heterodimeric proteins
formed of a HIF-a and HIF-b subunit (Wang et al, 1995). HIF-a
is regulated by intracellular oxygen levels; at physiological
oxygen tension (normoxia), two highly conserved proline resi-
dues within the oxygen-dependent degradation domain of the
HIF-a subunit (P402/564 on HIF-1a; P405/531 on HIF-2a) are
hydroxylated by prolyl hydroxylase domain (PHD) proteins.
Hydroxylated HIF-a is then recognised and ubiquitinated by the
von Hippel–Lindau (VHL) E3 ubiquitin ligase complex, resulting
in its degradation by the 26S proteasome (Salceda & Caro, 1997;
Maxwell et al, 1999; Jaakkola et al, 2001; Foxler et al, 2012).
Under low oxygen (hypoxic) conditions, the hydroxylase activity
of the PHD enzymes is inhibited; HIF therefore escapes hydroxy-
lation and degradation to initiate a transcriptional programme of
cellular response and adaptation to hypoxia.
Under conditions of chronic hypoxia, a negative regulatory feed-
back loop is initiated whereby free oxygen from inhibited mitochon-
drial respiration leads to overactivation of PHDs, causing HIF-a
degradation and a desensitised hypoxic response (Ginouves et al,
2008). However, neoplastic cells survive under conditions of chronic
tumour hypoxia by inhibiting the degradation of HIF (Bertout et al,
2008). This is exemplified by VHL mutations in clear cell renal
carcinomas, leading to sustained HIF-a expression and activity
(Rechsteiner et al, 2011). In non-small-cell lung cancer (NSCLC),
deregulation of the HIF negative feedback loop is far less charac-
terised, even though HIF-a protein expression is implicated as a poor
prognostic indicator (Giatromanolaki et al, 2001; Kim et al, 2005).
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The lung tumour suppressor protein LIMD1 is a member of the
Zyxin family of adaptor proteins, initially characterised as signal
transducers (Kadrmas & Beckerle, 2004) shuttling between the cyto-
plasm and nucleus. LIMD1 loss has been identified in lung, breast,
head and neck squamous cell carcinomas, and adult acute leukaemia
(Sharp et al, 2004, 2008; Spendlove et al, 2008; Ghosh et al, 2010b;
Liao et al, 2015), and its decreased expression in diffuse large B-cell
lymphoma has clinical significance to patient prognosis and disease
classification/stratification (Xu et al, 2015). Limd1-knockout mice
have increased lung tumour numbers and volume and decreased
survival rate compared to Limd1-expressing control mice when
either challenged with a chemical carcinogen or cross-bred with
KrasG12D mice (Sharp et al, 2008) validating its critical role in
normal cellular homeostasis. Furthermore, it has been reported that
silencing of LIMD1 in multidrug-resistant colorectal carcinoma cells
increased their chemosensitivity in vitro (Chen et al, 2014).
As a scaffold protein, LIMD1 exerts multiple tumour-suppressive
functions depending on its binding partners. Basal LIMD1 gene
expression is under the control of PU.1, a member of the Ets family of
transcription factors (Foxler et al, 2011). LIMD1 can repress cell cycle
progression through pRb-dependent and pRb-independent inhibition
of E2F (Sharp et al, 2004) and regulates Hippo signalling by binding
to LATS, causing sequestration of the Hippo kinase complex (Das
Thakur et al, 2010; Codelia et al, 2014; Jagannathan et al, 2016).
LIMD1 is also part of the Slug/Snail complex that regulates E-cadherin
transcription (Ayyanathan et al, 2007; Langer et al, 2008) in addition
to facilitating centrosomal localisation of BRCA2 to prevent aberrant
cellular proliferation (Hou et al, 2016). Our recent work has shown
that LIMD1 is a critical effector of microRNA (miRNA)-mediated gene
silencing, a process generally considered to be a global tumour-
suppressive mechanism (James et al, 2010; Bridge et al, 2017).
LIMD1 forms complexes with PHD2 and VHL to post-translation-
ally repress HIF-1a protein levels and therefore HIF-1a-mediated gene
activation (Foxler et al, 2012; Zhang et al, 2015). However, the patho-
physiological link between this mechanistic role of LIMD1 within the
PHD-LIMD1-VHL HIF regulatory complex and cancer is unknown.
Here, we report that LIMD1 expression is upregulated in hypoxia,
through a functional HIF-1a-specific hypoxic response element (HRE)
within the CpG island in its promoter. LIMD1 facilitates HIF-1a
protein degradation under hypoxic conditions by maintaining the
PHD2/VHL/HIF-1a degradation complex, thereby reducing HIF-1a-
driven gene activation. Utilising an RNAi-mediated knockdown-
rescue system, we have identified that inhibition of hypoxia-driven
increase in LIMD1 expression causes HIF-1a protein stabilisation and
HIF target gene activation. In vivo, inhibition of hypoxia-driven
LIMD1 expression results in larger and more vascularised xenograft
tumours. Finally, our data provide a molecular mechanistic insight
into clinico-pathological data indicating that LIMD1 loss or haplo-
insufficiency correlated with elevated HIF-1a-driven gene expression
within lung tumours is associated with poorer patient prognosis.
Results
LIMD1 is a HIF-1-responsive gene
Homeostatic signalling pathways often have in-built self-regulatory
feedback mechanisms to attenuate their activation (Yosef & Regev,
2011). With this in mind, we hypothesised that LIMD1 might be a
HIF target gene as well as a component of the degradation complex.
We therefore assessed endogenous LIMD1 expression in a panel of
cell lines exposed to 1% O2 (henceforth referred to as hypoxia),
including transformed/immortalised lines (A549, HeLa, HEK293 and
U2OS), non-transformed small airway epithelial cells (SAEC) and
primary human dermal fibroblasts (HDF). We observed an increase
in LIMD1 mRNA and protein expression in all cell lines in hypoxia
when compared to atmospheric oxygen (20% O2, herein referred to
as normoxia) using PHD2 as a positive control and PHD1 as a
hypoxia non-responsive gene (Figs 1A–C, and EV1A and B; Stiehl
et al, 2006).
In silico analysis of the LIMD1 promoter identified three putative
hypoxic response elements (HRE 1–3; Fig EV1H; Foxler et al, 2011).
To assess their functionality, we used a LIMD1 promoter-driven luci-
ferase reporter construct, spanning 1990-bp upstream from the
LIMD1 transcriptional start site [as predicted by the RefSeq
NM_014240.2, which corresponds to nucleotides 45634323-6323 on
the primary chromosome 3 ref assembly NC_000003.11 (Foxler
et al, 2011)] and encompassing all three predicted HRE elements
(Fig 1D). Within this construct, we created a series of ten consecu-
tive small internal deletions within the CpG Island that have previ-
ously been identified as containing transcriptional regulatory
elements (Foxler et al, 2011; Fig EV1I). These reporter constructs
displayed ~ threefold induction of wild-type LIMD1 promoter
activity in hypoxia compared to normoxia. However, deletion of the
31-bp D3 region that encompasses the predicted HRE3 ablated any
hypoxia-induced increase in luciferase activity (Fig EV1J). Further-
more, internal deletion of the three predicted HREs confirmed HRE3
to be the active hypoxia-responsive element within the LIMD1
promoter (Fig 1E). The position and sequence of this HRE is also
highly conserved, further supporting its functional importance
(Fig 1F and G).
We next determined which HIF-a paralogue was involved in
LIMD1 regulation by combining the LIMD1 promoter-driven luci-
ferase reporters (Foxler et al, 2011) with shRNA-mediated knock-
down of HIF-1a and HIF-2a. Depletion of HIF-1a, but not HIF-2a,
prevented induction of LIMD1 expression in hypoxia (Fig EV2A).
This finding was corroborated by ChIP and EMSAs, which further
demonstrated HIF-1 binding to the LIMD1 promoter (Fig 2A and B).
siRNA-mediated depletion of HIF-1a reduced LIMD1 protein and
mRNA expression under hypoxic and, to a lesser extent, normoxic
conditions in all cell lines examined (Figs 2C and D, and EV2B–E).
LIMD1 depletion did not affect HIF1A or HIF2A mRNA expression,
with the exception of an observed increase in HIF2A mRNA in HeLa
cells under hypoxic conditions (Fig EV2F–I). The decrease in LIMD1
expression in normoxia following si-HIF-1a demonstrates that HIF-1
activity is required for LIMD1 expression in normoxia, an observa-
tion that has been previously described for other genes (Pillai et al,
2011). Furthermore, under hypoxic conditions HIF preferentially
binds to gene loci that are already transcriptionally active to further
activate their expression (Xia & Kung, 2009). Thus, these data show
that under hypoxic conditions, HIF-1 binds the LIMD1 promoter to
increase its expression.
Under normoxic conditions, LIMD1 scaffolds PHD2 and VHL to
enable efficient degradation of HIF-1a (Foxler et al, 2012).
Given that LIMD1 is a hypoxia-responsive gene, we next per
formed co-immunoprecipitation assays to assess whether the
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Figure 1. LIMD1 expression is regulated by hypoxia.
The indicated panel of cell lines was exposed to either normoxia (20% O2) or hypoxia (1% O2) for up to 48 h prior to RNA and protein extraction.
A, B (A) LIMD1 mRNA and (B) protein levels were increased following hypoxic exposure.
C Densitometric analysis of (B).
D The LIMD1 promoter contains a hypoxic response element responsible for HIF binding and transcriptional activation of LIMD1. Three predicted HRE elements were
individually deleted within the context of the wild-type LIMD1 promoter-driven Renilla luciferase.
E Reporter constructs in (D) were expressed in U2OS cells and exposed to hypoxia for the indicated time-points. Luciferase activity was then assayed and normalised
to firefly control. Data are displayed normalised to the normoxic value for each construct. Deletion of the third HRE present within the LIMD1 promoter (DHRE3)
inhibited hypoxic induction of LIMD1 transcription.
F, G (F) Sequence alignment and (G) sequence logo of LIMD1 promoters from the indicated species demonstrate that the HRE3 consensus sequence is highly conserved.
Data information: Unless otherwise stated, data shown are mean  SEM, n = 3, *P < 0.05, **P < 0.01, ***P < 0.001, according to the Student’s t-test (A) or Holm–
Sidák post hoc tests, comparing time-points within each cell line (A and C) or comparing the VO group to every other genotype within each time-point (E), following
significant main effects/interactions of a mixed-model ANOVA. See Appendix Table S1 for a summary of statistical analysis.
Source data are available online for this figure.
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Figure 2. LIMD1 is a HIF-1-responsive gene.
A HIF-1 binds to the LIMD1 promoter. Chromatin immunoprecipitation assay (ChIP) of endogenous HIF-1a from paraformaldehyde cross-linked U2OS cells exposed to
16-h hypoxia, followed by qRT–PCR analysis of the indicated gene promoters.
B EMSA of nuclear extracts from U2OS cells exposed to normoxia (lanes 1 and 5) or 16-h hypoxia identified that HIF-1a but not HIF-2a bound the LIMD1 HRE
consensus sequence, causing a band supershift (ss). Wild-type unlabelled oligo probes that encompass the LIMD1 or PHD2 HRE were used as controls to compete out
the ss, and probes where the HRE sequences have been mutated (mLIMD1/mPHD2) were used to show specificity for HRE binding.
C siRNA-mediated depletion of HIF-1a but not HIF-2a reduces LIMD1 expression in both normoxia and hypoxia. qRT–PCR analysis of LIMD1 mRNA from U2OS cells
transfected with the indicated siRNA (40 nM) and maintained in normoxia (20% O2) or exposed to hypoxia (1% O2) for 24 h.
D Western blot analysis of protein from (C).
E LIMD1 endogenously complexes with PHD2, VHL, HIF-1a and HIF-2a. Endogenous LIMD1 was immunoprecipitated from HeLa cells in either normoxia or following
24-h hypoxia and co-immunoprecipitated proteins identified by immunoblot analysis.
Data information: Unless otherwise stated, data shown are mean  SEM, n = 3, *P < 0.05, **P < 0.01, according to Holm–Sidák-corrected one-sample Student’s t-tests,
comparing the mean of each gene’s mRNA expression to the theoretical value of 1. See Appendix Table S2 for a summary of statistical analysis.
Source data are available online for this figure.
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PHD2-LIMD1-VHL complex also exists in hypoxic conditions. Indeed,
LIMD1 co-precipitated with PHD2 and VHL under hypoxia (Figs 2E
and EV2J); HIF-1a and HIF-2a also co-precipitated with LIMD1,
which may be due to the increased protein stability of the HIF
proteins under this low oxygen tension. These data demonstrate
active engagement of the PHD-LIMD1-VHL complex with its HIF
target protein in hypoxia. However, HIF-1b did not co-precipitate
within this complex, indicating LIMD1 was facilitating HIF-a degra-
dation prior to heterodimerisation with the HIF-b subunit and inde-
pendent of oxygen tensions. Thus, in hypoxia, LIMD1 expression
facilitates formation of an active PHD2-LIMD1-VHL HIF-degradation
complex.
HIF-1-driven LIMD1 expression is required for negative
regulation of HIF in a hypoxic environment
LIMD1 protein expression has been previously shown to be signifi-
cantly reduced or lost in human lung and breast cancers (Sharp et al,
2004, 2008; Spendlove et al, 2008). This led us to hypothesise that a
decrease in the normal levels of LIMD1 protein expression as a result
of LIMD1 loss of heterozygosity (LOH) or promoter methylation
(Sharp et al, 2008) may disrupt the hypoxic PHD-LIMD1-VHL
complex, and exacerbate HIF-mediated gene expression and pro-trans-
forming effects in the context of a hypoxic tumour microenvironment.
To directly assay the effects of hypoxia-driven LIMD1 expression,
we utilised a lentiviral shRNA-mediated knockdown-rescue system
that concurrently expresses an shRNA and a cDNA (Foxler et al,
2012; Fig 3A schematic). We utilised this system to express an
shLIMD1 to deplete cells of endogenous LIMD1, whilst simultane-
ously re-expressing an RNAi-resistant (rr) Flag epitope-tagged LIMD1
that was under the control of the endogenous LIMD1 promoter,
which we previously identified as being an active and regulated
promoter sequence under both normoxic and hypoxic conditions
(Fig EV1I; Foxler et al, 2011). The promoter sequence contained the
wild-type HRE motif (HREwt); we also generated a version with a
mutated HRE sequence (HREmut; Figs 3A and EV3A). Ectopic LIMD1
expression in cells transduced with these vectors (where endogenous
LIMD1 is repressed by the shRNA) would therefore be potentially
enhanced (HREwt) or unchanged (HREmut) by hypoxia through HIF-1.
U2OS, HeLa and SAEC were transduced with the paired set of lenti-
viruses described and identified within this non-clonal population,
and LIMD1 controlled by the HREwt promoter had a twofold to three-
fold hypoxic induction of LIMD1 (Figs 3B–E and EV3B–E). In
contrast, mutation of the HRE within the LIMD1 promoter (HREmut)
significantly impaired hypoxic induction of LIMD1 in these lines. This
was coupled with an impairment of HIF-1a degradation under
increasing exposure to hypoxia in the HREmut lines compared to HREwt
(Fig 3B and F–H). Of note, the HREmut cells had increased expression
of HIF1A mRNA after 24 h in hypoxia compared to the HREwt cells
(Fig EV3F), which we postulate may be the result of increased HIF-1a
protein in this line further driving its own transcription (Koslowski
et al, 2011). The HREmut cell lines also exhibited increased HIF-driven
luciferase activity (Figs 3I and EV3G), endogenous HIF-1-driven gene
activation (Figs 3J and EV3H–K) and cumulative secreted VEGF-A
(Figs 3K and EV3L) when compared to the HREwt cells.
We then wished to ascertain whether the observed transcriptional
and phenotypic differences (Fig 3) were both HIF-specific and due to
the effects that LIMD1 expression was exerting on HIF-1a protein
turnover. Treatment with the translational inhibitor cycloheximide
(Cx) to assess the degradation rate of HIF revealed the HREmut line
had a significantly decreased rate of both HIF-1a and HIF-2a degrada-
tion compared to the HREwt line (Fig 4A and B). Furthermore, siRNA
depletion of HIF-1a ablated the differential gene expression of VEGF-A
between the lines (Fig 4C and D). Depletion of HIF-2a also decreased
VEGF-A expression, likely due to VEGF-A being a dual HIF-1 and HIF-
2 target gene (Hu et al, 2003). We conclude that the differences in HIF
stability and transcription observed between the HREwt and HREmut
cell lines were caused by the hypoxic induction of LIMD1 via its HRE.
To exclude the possibility that the miRNA-silencing function of
LIMD1 (James et al, 2010) was complicit in this observed effect, we
utilised luciferase reporter constructs containing the HIF-1/2a
30UTRs (as defined from RefSeq identifiers NM_001530.3 and
NM_001430.4, respectively). There were no differences in HIF-a
30 UTR regulation in LIMD1-expressing or null cells, regardless of
oxygen tension (Fig 4E), indicating that LIMD1 was only affecting
HIF-a levels post-translationally and not post-transcriptionally in
this experimental context of subtle but significant change in LIMD1
protein induction [twofold to threefold increase (Fig 3B–E)].
▸Figure 3. Induction of LIMD1 in hypoxia inhibits HIF-1-mediated gene expression.A A combinatorial RNAi–cDNA re-expression lentiviral cassette was utilised to create isogenic cell lines where LIMD1 was either responsive or unresponsive to
hypoxia. Endogenous LIMD1 was depleted by shRNA, whilst concurrently a Flag-LIMD1 cDNA was expressed that was driven by the sequence of its own
endogenous promoter.
B U2OS, HeLa and SAEC were transduced with these lentiviral cassettes to create the HREwt and HREmut paired cell lines.
C–E Western blot quantification of LIMD1 relative to b-actin and normalised to 0-h time-point for each cell line.
F–H Western blot quantification of HIF-1a relative to b-actin and normalised to 4-h time-point for each cell line.
I Impaired hypoxic induction of LIMD1 induction increases HRE-luciferase activity. U2OS isogenic cell lines were co-transfected with a synthetic HRE-luciferase
(pNL-HRE) and pGL3 firefly normalisation plasmid, prior to exposure to hypoxia. Luciferase activity was assayed and normalised against HRE activity in the HREwt
line. After 24-h hypoxic exposure, the HREmut line had significantly increased luciferase activity compared to the HREwt line.
J Impaired hypoxic induction of LIMD1 induction increases expression of HIF target genes. RNA was extracted from the U2OS isogenic cell lines following 24-h
hypoxic exposure, and a panel of HIF-1 downstream targets were quantified by qRT–PCR. The HREmut line had significantly increased HIF-1-driven gene
expressions compared to the HREwt line.
K Impaired hypoxic induction of LIMD1 induction increases VEGF-A secretion. U2OS isogenic cell lines were incubated in hypoxia for 48 h and VEGF-A secretion was
quantified by ELISA, identifying the HREmut line as secreting a significantly increased VEGF-A protein when compared to the HREwt line.
Data information: Unless otherwise stated, data shown are mean  SEM, n = 3, *P < 0.05, **P < 0.01, ***P < 0.001, according to Holm–Sidák post hoc tests, comparing
genotypes at each time-point (I and K) or at each gene (J), following significant main effects/interactions of a mixed-model ANOVA. See Appendix Table S3 for a summary
of statistical analysis.
Source data are available online for this figure.
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Figure 4. LIMD1 regulates HIF-1a at the post-translational level.
A The hypoxic induction of LIMD1 facilitates HIF protein degradation. Western blot analysis of HREwt and HREmut U2OS lines exposed to hypoxia and the translation
inhibitor cycloheximide (Cx) treatment for the indicated time-points. HIF-1a protein is degraded more efficiently in the HREwt line where LIMD1 expression is
increased in hypoxia as detected by immunoblot.
B HIF-1a rate of decay (ROD) is significantly slower in HREmut U20S compared to HREwt. Densitometric analysis of HIF-1a protein, double normalised to b-actin and
0 min Cx treatment in each line, was used to calculate ROD (D relative protein densitometry per minute) of HIF-1a protein between 0 and 30 min of Cx treatment.
C, D (C) The increase in HIF target gene expression in the HREmut lines is due to HIF protein expression. siRNA (40 nM) targeting HIF-1a and HIF-2a was transfected
into the HREwt and HREmut cell lines, and protein depletion was confirmed by immunoblot, which resulted in decreased expression of VEGF mRNA as analysed by
qRT–PCR from the simultaneous extraction of RNA (D).
E LIMD1 expression does not affect miRNA silencing of HIF-1a and HIF-2a 30UTR in normoxia or hypoxia. The 30UTR of either HIF-1a or HIF-2a was cloned into the
psiCheck2 luciferase vector. These were then transfected into LIMD1-expressing control (LIMD1+/+) or LIMD1-knockout (LIMD1/) HeLa cells and luciferase activity
assayed. Expression of LIMD1 did not affect the stability or silencing of either the HIF-1a or HIF-2a 30UTR-containing reporters.
Data information: Unless otherwise stated, data shown are mean  SEM, n = 3, *P < 0.05, ***P < 0.001, according to the Student’s t-test (B) or Holm–Sidák post hoc
tests, comparing siRNA treatments within each combination of genotype and time, following significant main effects/interactions of a mixed-model ANOVA. See
Appendix Table S4 for a summary of statistical analysis.
Source data are available online for this figure.
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Together, these data reveal that inhibition of the HIF-1/LIMD1 feed-
back loop causes an increased cellular hypoxic HIF phenotype
in vitro, demonstrating that increased LIMD1 protein expression in
hypoxia is necessary for correct modulation of HIF-1 expression and
signalling in a hypoxic environment.
Ablation of HIF-driven LIMD1 expression promotes
tumour growth
We next investigated the physiological relevance of this newly iden-
tified hypoxic HIF-1–LIMD1 negative feedback loop using in vivo
xenograft tumour growth as a model system. LIMD1 is a lung
tumour suppressor, with decreased mRNA and protein expression
shown to occur in a large proportion of lung adenocarcinomas
(Sharp et al, 2008). For our xenograft model, we therefore utilised
the A549 lung adenocarcinoma cell line. A549 LIMD1-HREwt and
A549 LIMD1-HREmut cell lines were created as described above. The
transduced cell lines were validated in vitro, where ablation of the
hypoxic induction in LIMD1 expression in the HREmut line increased
synthetic HIF-1-driven luciferase activity, HIF-1-responsive genes
and secreted VEGF (Fig 5A–C). These findings also corroborated the
results obtained in U2OS and HeLa cells (Figs 3 and EV3).
Subcutaneous xenografts were established on the flanks of
SCID/beige mice from either the A549 LIMD1 HREwt or HREmut cell
lines. Xenografts from A549 HREmut cells (which have an impaired
HIF–LIMD1 negative feedback loop) had increased age-matched
endpoint tumour volumes compared to A459 HREwt cells (which
have an intact HIF–LIMD1 negative feedback loop; Fig 5D). The
effect on in vivo tumour growth was not due to intrinsic dif-
ferences in proliferation rates as HREwt and HREmut cells had simi-
lar growth rates in in vitro proliferation assays and in colony
formation assays under either normoxia or hypoxia (Fig EV4A and
B). Endomucin staining, as a marker of blood vessels, revealed
increased vasculature in HREmut A549-derived xenografts (Fig 5E
and F) and was associated with increased endomucin mRNA
expression (Fig 5G) along with an increased HIF-1-mediated gene
expression profile of pro-angiogenic and glycolytic genes (Figs 5H–
J and EV4C–O). HIF1A mRNA expression was not altered upon
LIMD1 loss (Fig EV3F), demonstrating that the increase in HIF-1-
driven gene expression was not due to increased HIF-1a transcrip-
tion. Together, these data indicate that ablation of this HIF-1–LIMD1
negative regulatory feedback mechanism in vivo increases tumour
growth and vascularisation.
LIMD1 is a prognostic indicator in NSCLC
Finally, to investigate the clinical relevance and significance of our
in vitro and in vivo findings in NSCLC, we examined LIMD1 protein
expression in a tissue microarray of 276 lung cancer patients and
investigated correlation with patient outcome (representative stain-
ing Fig 6A; marker distribution Fig 6B). In agreement with previous
studies, LIMD1 protein expression was detected in both nuclear and
cytoplasmic compartments (Sharp et al, 2008; Spendlove et al,
2008). Kaplan–Meier survival analysis demonstrated that patients
exhibiting low LIMD1 expression within this cohort had significantly
worse overall survival compared to those with high LIMD1 expres-
sion (P = 0.045; Fig 6C). Immunohistochemical analysis of HIF-1a
and downstream angiogenic marker VEGF-A was not significantly
correlated with LIMD1 expression in this cohort; however, high
VEGF expression was correlated with poor patient prognosis
(P = 0.045; Appendix Fig S1, Fig EV5A–C).
We next interrogated The Cancer Genome Atlas (TCGA) datasets
to assess LIMD1 loss in a much larger cohort of NSCLC. First, gene
copy number analysis of LIMD1 and a number of other well-charac-
terised tumour suppressor genes in lung adenocarcinoma (LUAD)
and squamous cell carcinoma (LUSC) cohorts (n = 512 and
n = 498, respectively) demonstrated that single (shallow) or bi-
allele (Ghosh et al, 2008) deletion of the LIMD1 gene occurred in
47.1% (LUAD) and 85.4% of patients (LUSC; Figs 6D and EV5D).
Regression analysis demonstrated correlation between LIMD1 copy
number and reduced mRNA expression (Fig EV5E and F); therefore,
lung adenocarcinoma patients were stratified into risk groups (quar-
tiles) based on mRNA abundance intensities, and patient survival
was determined using a Cox proportional hazards model. We
▸Figure 5. Increased LIMD1 expression in hypoxia inhibits tumour growth and vascularisation.A Impaired hypoxic induction of LIMD1 induction increases HRE-luciferase activity in lung adenocarcinoma cells. Isogenic HREwt and HREmut A549 cell lines were co-
transfected with a synthetic HIF-1-driven luciferase (pNL-HRE) and pGL3 firefly normalisation plasmid, prior to exposure to hypoxia. Luciferase activity was assayed
and normalised against HRE activity in the HREwt line.
B Impaired hypoxic induction of LIMD1 induction increases endogenous HIF-mediated gene expression. RNA was extracted from the isogenic cell lines following 24-h
hypoxic exposure, and the expression of a panel of HIF-1 target genes was quantified by qRT–PCR. The HREmut line had significantly increased HIF-1-driven gene
expression compared to the HREwt line.
C Impaired hypoxic induction of LIMD1 induction increases VEGF-A secretion in lung adenocarcinoma cells. The isogenic cell lines were incubated in hypoxia for 48 h, and
VEGF secretion was quantified by ELISA, identifying the HREmut line as secreting a significantly increased level of VEGF-A protein when compared to the HREwt line.
D Impaired hypoxic induction of LIMD1 induction increases 3D tumour growth in vivo. Eight- to 12-week-old female SCID/beige mice were injected subcutaneously
with 5 × 109 A549 HREwt or HREmut cells and subsequent xenograft growth measured. HREwt-derived xenografts were smaller in volume compared to the HREmut
where LIMD1 expression was unresponsive to hypoxia.
E HREwt-derived xenografts have lower blood vessel density compared to HREmut-derived xenografts. Xenografts were snap frozen in liquid nitrogen, sectioned and
stained with endomucin (red) and DAPI (blue) (upper panels). Lower panels show endomucin staining in white for visual clarity. Scale bar, 100 lm.
F Blood vessels were manually counted throughout the entire section and xenograft cross-sectional area calculated.
G–J (G) HREwt-derived xenografts have lower expression of the blood vessel marker endomucin. RNA was extracted from snap-frozen xenografts and analysed by
qRT–PCR. In addition, HREwt xenografts also had lower expression of the HIF-driven genes (H) VEGF-A, (I) HK1 and (J) PDK1. n = 15 (HREwt) and n = 14 (HREmut).
Data information: Unless otherwise stated, data shown are mean  SEM, n = 3, *P < 0.05, **P < 0.01, ***P < 0.001, according to Holm–Sidák post hoc tests, comparing
genotypes at each time-point (A and C) or at each gene (B), following significant main effects/interactions of a mixed-model ANOVA (A and C) or standard two-way
ANOVA (B); alternatively, data in panel (D) were analysed with a Mann–Whitney U-test, and panels (F-J) were analysed with separate Welch-corrected Student’s
t-tests. See Appendix Table S5 for a summary of statistical analysis.
Source data are available online for this figure.
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determined that patients in the risk group exhibiting high LIMD1
expression (High Exp) had increased overall survival, whereas
patients exhibiting low LIMD1 expression (Low Exp) had reduced
overall survival (log-rank P = 0.021, HR 0.6; Fig 6E).
To assess the impact of LIMD1 loss on HIF regulation and
outcome in these patients, we analysed the TCGA LUAD cohort to
identify hypoxia/HIF signature genes correlated with low LIMD1
expression. We identified a strong inverse correlation between
LIMD1 and HIF target genes SLC2A1, GAPDH and IGF2BP2 mRNA
expression (Fig 6F–H). Kaplan–Meier analysis of survival of patients
stratified by expression of these genes revealed that patients with
the highest expression of these genes have significantly worse over-
all survival compared to patients who demonstrate the lowest
expression (Fig 6I–K).
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Figure 5.
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To complement the bioinformatic analysis of patient tumours, we
performed cell line-based in vitro analysis of the gene expression
changes that occur in a primary lung epithelial cell background
following a reduction in LIMD1 expression. We used siRNA to knock
down LIMD1 in primary human lung bronchial epithelial cells
(HBEC) and performed micro-array analysis to identify the resultant
gene ontology changes. Due to the cell type used in this analysis, this
models the role of LIMD1 loss in lung SCC. Differentially expressed
genes and associated pathways following depletion of LIMD1 were
analysed by ingenuity pathway analysis (IPA), and this identified
upregulation of HIF-1a and a network of HIF-1 interactions following
LIMD1 loss (Appendix Figs S2 and S3, and Dataset EV1).
In summary, these findings reveal the existence of a previously
uncharacterised tumour-suppressive, negative regulatory feedback
loop in which LIMD1 facilitates HIF degradation in hypoxia (Fig 7).
These findings add another level to the rapidly growing number of
pathways and processes that regulate HIF. This is the first example
of the main scaffold protein LIMD1 within the regulatory PHD2-
LIMD1-VHL complex being itself regulated by HIF and therefore
providing this regulatory triad with an intrinsic homeostatic nega-
tive regulatory functionality, which when deregulated contributes to
lung adenocarcinoma tumour growth.
Discussion
We have previously shown that the scaffold protein LIMD1 is a criti-
cal component of the HIF-degradation complex (Foxler et al, 2012).
In this study, we have demonstrated that LIMD1 expression is
induced by HIF-1 under hypoxic conditions, forming a negative feed-
back loop to degrade HIF. HIF-1-driven LIMD1 expression enables
the cell to degrade HIF-1a under conditions of chronic hypoxia to
prevent protracted HIF-1 activation, frequently associated with an
oncogenic phenotype. In a xenograft model for tumorigenesis, abla-
tion of the hypoxic inducibility of LIMD1 expression and subsequent
loss of hypoxic HIF-1a protein regulation caused increased tumour
vasculature and growth. From a clinical perspective, decreased
LIMD1 expression correlates with increased expression of HIF target
genes SLC2A1, GAPDH and IGF2BP2, each of which correlates with
significantly worse survival outcomes for patients.
By virtue of its scaffold function, the cellular processes and path-
ways that LIMD1 regulates are dependent on its protein partners.
HIF-a is post-transcriptionally regulated (Gorospe et al, 2011),
including by microRNA-20b, microRNA-199a and microRNA-424
(Rane et al, 2009; Cascio et al, 2010; Ghosh et al, 2010a). Therefore
to rule out the possibility that the miRNA-silencing function of
LIMD1 (James et al, 2010) was contributing to the observations
made, we identified that loss of LIMD1 does not affect the stability
nor silencing of HIF1A/HIF2A mRNA. LIMD1’s multiple tumour-
suppressive functions and its discrimination between binding part-
ners are likely to be regulated by different signalling cascades, with
multiple phosphorylation events on LIMD1 having already been
identified (Huggins & Andrulis, 2008; Sun & Irvine, 2013). However,
any post-translational modification events that promote LIMD1 to
function preferentially in HIF regulation are yet to be elucidated, but
may stem from a hypoxia-/HIF-activated signalling cascade
(Wouters & Koritzinsky, 2008; Lee et al, 2012; Xu et al, 2017).
LIMD1 has few reported coding sequence mutations and none
that correlate with loss of function (Huggins et al, 2007; Ghosh
et al, 2008). Such data suggest that gene dosage and thus small but
significant changes in protein levels may be important in disease
aetiology. Loss of total gene expression is frequently observed,
where reduced LIMD1 gene copy number and mRNA expression
occur in a significant proportion of lung carcinomas (Sharp et al,
2008). In this study, we have identified that a reduction in LIMD1
expression (through ablation of the hypoxic responsiveness of
LIMD1 promoter) is sufficient to cause a HIF-mediated pathological
transcriptome and phenotype in the form of increased tumour size
and vasculature.
The regulation of HIF under normoxic conditions is well charac-
terised (Salceda & Caro, 1997; Maxwell et al, 1999); however, the
mechanism of HIF degradation under long-term hypoxic conditions
is still poorly defined at the molecular level, even less so with
respect to the physiological relevance. However, our new data show
that discrete regulatory processes such as the HIF/LIMD1 negative
feedback loop described here can modulate HIF activity under
chronic hypoxic conditions. Biological pathways often have in-built
negative feedback loops whereby a transcription factor induces the
expression of an upstream negative regulator (Yosef & Regev, 2011);
such a negative feedback loop exists for the HIF proteins and the
hypoxic response (Marxsen et al, 2004; Stiehl et al, 2006; Tan et al,
2008; Nakayama et al, 2009). PHD2 depletion under hypoxia results
in stabilisation of HIF-1a (Stiehl et al, 2006), demonstrating HIFs
can be actively degraded and regulated independent of oxygen
tensions. Indeed, the complexity of HIF regulation via the hydroxy-
lation–ubiquitination degradation pathway is becoming increasingly
clear, with the identification of a plethora of HIF regulators, more
recently including Siah2, SHARP1 and RHOBTB3 (Nakayama et al,
2009; Montagner et al, 2012; Zhang et al, 2015).
Expression of HIF-a mRNA has historically been described as
constitutive; however, a growing number of studies are demonstrat-
ing the existence of factors that regulate HIF-a mRNA (Uchida et al,
▸Figure 6. Loss of LIMD1 expression is a poor prognostic indicator in lung cancer.A, B Representative immunohistochemistry (IHC) staining of cores for LIMD1 that were scored in the 276 patient sample TMA to ascertain relative expression (H-score)
within the cohort (B). Scale bar 100 lm; 20 lm on zoom panel.
C Kaplan–Meier analysis identified that patients stratified as having low LIMD1 expression (weak staining) exhibit poorer overall survival compared to high (intense staining).
D Copy number alterations of LIMD1 and other validated tumour suppressor genes from a lung adenocarcinoma (LUAD) cohort, publically available from TCGA.
E Stratification of TCGA LUAD cohort into quartiles based on LIMD1mRNA expression (where Q1 = lowest expression quartile, Q3 = highest expression quartile)
demonstrates worse overall survival for patients within the lowest LIMD1-expressing quartile (Low Exp) compared to the highest LIMD1-expressing quartile (High Exp).
F–H (F) Correlation analysis of LIMD1 mRNA expression in patients from (D) identified a significant inverse correlation between LIMD1 and HIF target genes SLC2A1, (G)
GAPDH and (H) IGF2BP2. The violin plots show the local density of data: black bars represent the IQR, red dot is the mean and white dot is the median.
I–K (I) Stratification of TCGA LUAD cohort into quartiles based on SLC2A1, (J) GAPDH and (K) IGF2BP2 expression demonstrates worse overall survival for patients within
the highest expressing quartile (High Exp) compared to the lowest expressing quartile (Low Exp) for each gene.
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2004; Chamboredon et al, 2011; Hamidian et al, 2015). From our
investigations, the LIMD1 HREmut-derived A549 xenografts had an
increase in HIF2A mRNA expression compared to the HREwt
controls. We propose that inhibition of hypoxia-driven LIMD1
expression, resulting in enhanced HIF-a protein stability, drives
HIF2A mRNA expression. Stabilisation of HIF-a protein and hypoxia
has previously been described as inducers of HIF2A mRNA expres-
sion (Hamidian et al, 2015; Mohlin et al, 2015).
Many HIF-activated genes have been identified as prognostic and
diagnostic markers. The oncogenic properties of HIF in cancer and
disease have resulted in an abundance of potential therapeutics in
development and clinical trials that target HIF at the transcriptional,
translational, post-translational and functional levels (Masoud & Li,
2015; Nakazawa et al, 2016). Indeed, the hypoxic HIF signalling
pathway is already a therapeutic target with multiple drugs
currently in clinical trials (Wilson & Hay, 2011; Bryant et al, 2014;
Masoud & Li, 2015). VEGF expression is a marker of poor prognosis
in NSCLC (Kaya et al, 2004); as such, VEGF-targeted therapies are
widely used to target VEGF-mediated angiogenesis, although the
details of how they exert their effects are not yet clearly defined
(Ellis & Hicklin, 2008). In some cases, vasculature promotion and
normalisation have been demonstrated to yield greater therapeutic
efficacy (Wong et al, 2015, 2016). In our small cohort of 276
NSCLC, high VEGF expression was correlated with poor survival,
with 80% of the cohort demonstrating high VEGF expression.
Analysis of a TCGA lung adenocarcinoma cohort determined an
inverse correlation between expression of LIMD1 and HIF target
genes SLC2A1, GAPDH and IGF2BP2. Overexpression of glucose
transporter 1 (GLUT-1), the uniporter protein encoded by the
SLC2A1 gene, is correlated with poor survival in most solid tumours
(Wang et al, 2017), and selective GLUT-1 inhibition has been
demonstrated to inhibit glucose uptake and reduce viability of lung
adenocarcinoma and squamous cell carcinoma cell lines in vitro and
in vivo (Goodwin et al, 2017). Correlative studies have also deter-
mined upregulation or de novo expression of the IGF2BP family of
oncofetal proteins across a number of solid tumours to be associated
with tumour aggressiveness, metastasis and poorer overall survival
(Bell et al, 2013). GAPDH overexpression is also associated with
reduced patient survival (Guo et al, 2013), and therapeutic targeting
of GAPDH has been demonstrated to have clinical application in
both hepatocellular and colorectal cancers (Ganapathy-Kanniappan
et al, 2012; Yun et al, 2015). Our data correlate LIMD1 loss with
overexpression of each of these HIF target genes, and as such hold
potential for both stratification of patients based on a LIMD1low,
SLC2A1high/IGF2BP2high/GAPDHhigh genetic profile and targeted
therapies based upon this HIF target gene signature.
Taken together, our findings hold significant impact for the aeti-
ology of LIMD1-negative lung cancers and hold the potential for
advances in the diagnosis and prognosis of such cancers with
respect to deregulated HIF regulation and associated oncogenic
phenotypes, and subsequently hypoxia-targeted therapies.
Materials and Methods
Bioinformatic analysis
As a reference point for referring to positions within the LIMD1
promoter, the unconfirmed transcriptional start site (TSS) was
assigned according to the NCBI reference sequence NM_014240.2.
This corresponds to nucleotide 45636323 on the primary chromo-
some 3 ref assembly NC_000003.11 and is 49-bp upstream from the
AUG translation initiation codon. The human LIMD1 promoter,
which was preliminarily designated as 2.5-kbp upstream of the ATG
translation initiation codon, was scrutinised using the Ensembl
Genome Browser (http://www.genome.ucsc.edu) for the presence
of CpG Islands, utilising the default software thresholds. The in silico
screen for transcription factor binding motifs within the promoter
was performed using the MatInspector software programme (http://
genomatix.de) using the Matrix Family Library Version 8.1. HRE3
Figure 7. Proposed model of the HIF-1–LIMD1 negative regulatory feedback mechanism.
HIF-1a is stabilised in hypoxia and heterodimerises with HIF-1b, forming an active HIF-1 transcription factor complex with CBP/p300. HIF-1 binds to hypoxic response
elements (HRE) within the promoters of genes that are required for hypoxic survival and adaptation, increasing their gene expression. Classically, these include genes
required for metabolic adaptation and angiogenesis. Here, we identify that the tumour suppressor gene LIMD1 is also a HIF-1-responsive gene, and in hypoxia, its expression
is increased at both the mRNA and protein levels. This increased expression facilitates formation of a hypoxic PHD2-LIMD1-VHL degradation complex, facilitating hypoxic
HIF-1a degradation. In turn, this attenuates the tumorigenic cellular adaption to hypoxia and subsequent tumorigenesis, thus identifying a new level of complexity of a
tumour-suppressive mechanism of LIMD1.
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multiple sequence alignment was performed using LIMD1 promoter
sequences from the UCSC Genome Browser and aligned using Clustal
Omega. HRE3 sequence logo was generated using WebLogo.
Copy number analysis (CBioportal)
Provisional TCGA LUAD and LUSC datasets were accessed and
downloaded from cbioportal.org. The datasets included 512 (LUAD)
and 498 (LUSC) patients. Focally deleted genes altered in lung
adenocarcinoma and squamous cell carcinoma were selected from a
study by Campbell et al (2016) and used, along with LIMD1, to
query LUAD and LUSC provisional datasets (via http://www.
cbioportal.org). Putative copy number alterations from GISTIC were
used to identify the following copy number categories: amplifi-
cation, gain, diploid, shallow deletion and deep deletion for each
gene. The percentage of samples displaying each category was then
calculated for each gene. For each sample, linear LIMD1 copy
number values were plotted against LIMD1 mRNA expression
values (log2-transformed RNA Seq V2 RSEM). Pearson’s r correla-
tion analysis was performed using GraphPad Prism version 7.04.
The Cancer Genome Atlas (TCGA) analysis
All analyses were conducted in the R statistical environment
(v 3.3.2).
Data
Level-3 RNA-Seq data for human lung adenocarcinoma (LUAD)
primary tumours (n = 517) were downloaded from the TCGA using
the TCGAbiolinks R package (Cancer Genome Atlas Research
Network, 2014; Colaprico et al, 2016).
Correlation
Pearson’s product-moment correlation coefficient and P-value of
pairwise comparisons between the mRNA abundance values of
LIMD1 and hallmark hypoxia gene set (GSEA) were computed.
Survival
Patients were stratified into three risk groups based on the quartile
values of mRNA abundance densities. The prognostic values of
SLC2A1, GAPDH and IGF2BP2 in lower quartile (n = 127) and
upper quartile (n = 127) risk groups were assessed using a Cox
proportional hazards regression model, with P-values estimated
using log-rank test. The survival modelling and Kaplan–Meier anal-
yses were conducted using the survival package (v 2.41-3;
Therneau & Grambsch, 2000). All analyses were conducted for a
5- and 10-year survival timeframe.
Cell culture
U2OS, HEK293T, HeLa and A549 cells were maintained in D-MEM
(Sigma) supplemented with 10% FCS and 1% pen/strep solution in
a humidified 37°C incubator and 5% CO2. SAEC were maintained
in complete small airway epithelial cell growth medium (Lonza).
Cells were regularly tested for mycoplasma. Hypoxic incubations
were carried out at 1% O2 within a humidified ProOx110 controller
chamber (BioSpherix Ltd, New York, USA). Cells were transfected
using Viafect (Promega E4981) with a 3:1 ratio of Viafect:DNA.
Promoter cloning
Site-directed mutagenesis reactions were performed using Quik-
Change XL Site-Directed Mutagenesis Kit (Stratagene #200517) as
per the supplied protocol as confirmed by sequencing (Source
Bioscience UK Limited, Nottingham). Primer sequences are supplied
in Appendix Table S10.
shRNA plasmids generation and transduction
shRNA sequences (supplied in Appendix Table S10) were annealed
and ligated into psiRNA-DUO plasmid (Invivogen # ksirna4-gz3)
with Acc65I and HindIII (NEB #R0599S and #R0104S).
The knockdown-rescue shRNA lentiviral system was a kind gift
from Greg Longmore (Feng et al, 2010). The lentiviral system allows
simultaneous shRNA-mediated knockdown of an endogenous target
with concurrent rescue of the same RNAi-resistant target. Lentiviral
plasmids containing a LIMD1 targeting shRNA with concurrent
RNAi-resistant LIMD1 cDNA expression was modified so that
expression of the cDNA was driven by the endogenous LIMD1
promoter. A 2-kb region upstream of the LIMD1 ATG translation
initiation codon was amplified using the primers ggagcgGTCGAC
CAGGCACTTGGCATACAGATATGGTC (SalI forward) and cgctccGA
ATTCGCTGCAGACAGGTGTCCGGGCCTAG (EcoR1 reverse). The
ubiquitin C promoter from the pFlRu plasmid that drives the rescue
expression was then replaced with the amplified LIMD1 promoter.
To create a rescue plasmid with a mutated HRE, site-directed muta-
genesis with the already described DHRE3 primers was used.
Lentivirally transduced cell lines were created as previously
described (Foxler et al, 2012).
Luciferase assays
The HRE-pGL3 luciferase construct containing three copies of the
HRE from the phosphoglycerate kinase promoter was a kind gift
from Thilo Hagen (Department of Biochemistry, National University
of Singapore). The HRE element was subcloned into the pNL1.1
vector (Promega). Cells were co-transfected with 50 ng of HRE
reporter vector and 5 ng firefly normalisation reporter plasmid DNA
per well of a 12-well plate and lysed 36 h post-transfection in 1×
Passive Lysis Buffer (Promega E1941). Luciferase activity assayed
using a Nano-Glo Dual-Luciferase Reporter Assay System (Promega
N1610). The 30UTR sequences for HIF-1a and HIF-2a were PCR
cloned from a HeLa cell cDNA and into the psiCheck2 vector using
50XhoI and 30NotI sites incorporated into the PCR primers. Primer
sequences are supplied in Appendix Table S10.
qRT–PCR
All qRT–PCR was performed using a 1-step RT–qPCR method
(Promega A6020). All reactions were performed in triplicate with
20 ng of RNA 200 nM forward and reverse primers in a 25 ll reac-
tion volume run on an ABI7000 instrument (Applied Biosystems).
Gene-specific primers were designed to span an exon boundary and
data normalised to the housekeeping genes RNA polymerase II.
RNA extractions from cells were performed using a column-based
purification (Promega Z6011) and from xenograft tissue following
homogenisation in Tripure (Roche Applied Science 11667157001)
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and aqueous phase extraction. The list of primers used appear in
Appendix Table S10.
VEGF-A ELISA
ELISAs were performed on cell supernatants following 48-h hypoxia
utilising the Human VEGF-A Quantikine ELISA Kit (R&D Systems
DVE00).
Chromatin immunoprecipitation (ChIP)
1 × 107 cells were stimulated overnight in hypoxia. Formaldehyde
(1% v/v) was added to cross-link protein–DNA for 10 min at 37°C and
was quenched with ice-cold 0.125 M glycine/PBS. Cells were
harvested in 1 ml harvesting buffer (0.125 M glycine, 1 mM EDTA
and protease inhibitors in PBS) and pelleted by centrifugation at
3,500 g for 10 min at 4°C. The cell pellet was resuspended in 100 ll of
lysis buffer (50 mM Tris–HCl pH8.0, 1% SDS, 10 mM EDTA plus
protease inhibitors) and incubated on ice for 10 min. 50 ll of dilution
buffer (20 mM Tris–HCl pH8.0, 1% Triton X-100, 2 mM EDTA,
150 mM NaCl plus protease inhibitors) was added and lysates soni-
cated on ice to shear the DNA to 200–600 bp. Lysates were cleared of
insoluble material by centrifugation at 13,000 g for 10 min at 4°C. An
input sample was taken, and the remaining soluble chromatin contain-
ing supernatant diluted to 1 ml with dilution buffer and added to an
antibody-conjugated IP matrix and incubated overnight at 4°C with
rotation. IP matrix beads were washed 6 × 1 ml RIPA and protein–
DNA complexes eluted in 2 × 75 ll elution buffer (1% SDS, 0.1 M
NaHCO3) for 15 min at room temperature with rotation. Cross-links
were then reversed for 6 h at 65°C with NaCl (0.2 M), followed by
incubation with 20 lg proteinase K, 40 mM Tris–HCl pH 6.5, 10 mM
EDTA. DNAwas then purified using the Qiagen PCR purification kit.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assays were performed using the
method described in Foxler et al (2011) following incubation of cells
at 1% O2 for 24 h, prior to nuclear extraction. MG132 was included
in all buffers to prevent degradation of HIF-1a. 5 lg of nuclear
extracts was incubated in a total volume of 20 ll HIF binding buffer
(50 mM KCl, 10 mM Tris pH 7.7, 5 mM DTT, 1 mM EDTA, 2 mM
MgCl2, 5% glycerol, 0.03% NP-40 and 400 ng salmon testes DNA)
with 1 ll of HIF-1a or HIF-2a antibodies. Binding reactions were
pre-incubated on ice for 30 min prior to addition of 32P-labelled
probe with an overnight incubation at 4°C. Complexes were then
resolved on 5% polyacrylamide gels (acrylamide: bisacrylamide
30:0.8) at room temperature. Gels were dried and developed using a
Fuji-film LAS-3000 phosphor-imager. For specificity of the HIF bind-
ing site and for competition assays, probes with the HIF site mutated
were also used. Probes were synthesised by Sigma-Aldrich and
listed in Appendix Table S10.
Immunoblotting
Protein lysates were analysed using SDS–PAGE using standard
Western blotting protocols. The list of antibodies used appear in
Appendix Table S11.
Cycloheximide (Cx) treatment
Cells were plated 24 h prior to treatment with cycloheximide
(200 lg/ml; sc-3508). Media containing 400 lg/ml Cx were incu-
bated in 1% O2 for 24 h to allow de-oxygenation prior to addition to
an equal volume of cell media. Lysates were taken immediately
prior to Cx addition (start-point) and following the last time-point
without Cx added (endpoint) to disseminate between drug-induced
and endogenous HIF-a protein turnover. Cx was added so that all
drug treatment times finished at the same time. HIF-a protein
expression was assayed by Western blot and quantified with ImageJ
software and normalised to b-actin loading control. The rate of turn-
over was calculated from the gradient of log[HIF-a protein] against
time.
Animal studies
All animal experiments conformed to the British Home Office
Regulations (Animal Scientific Procedures Act 1986; Project
License PPL 70/7263 to Prof Nick Lemoine). Trial experiments and
experiments done previously were used to determine sample size
with adequate statistical power. Twenty-five mice for each group
were studied in total in two independent experiments. Eight- to
12-week-old female SCID/beige mice (Harlan Laboratories) were
given a subcutaneous injection of 5 × 106 transduced A549 cells in
100 ll PBS into the right flank for subcutaneous tumour growth.
Calliper measurements were taken over time, and the experiment
reached an endpoint when the first tumour measurement of maxi-
mum length x maximum breadth exceeded the maximum size
dictated by the Project licence. Mice were killed by Schedule 1
cervical dislocation. Xenografts were then immediately excised
prior to the onset of rigour mortis. Xenografts were bisected and
half flash frozen in liquid N2 or frozen on dry ice in 0.8 ml
Tripure for subsequent RNA extractions. Snap-freezing of fresh
subcutaneous tumours is the best recognised method for subse-
quent effective blood vessel immunostaining. This method avoids
many of the limitations of prefixing the tissue that can actually
reduce antigenicity when it comes to immunostaining for blood
vessels.
Xenograft analysis
Snap-frozen xenograft samples were sectioned into 4–6 lM
sections (Pathology Department, Bart’s Cancer Institute, Queen
Mary University of London). Sections were fixed in ice-cold
acetone for 10 min and stained overnight with the endothelial
blood vessel marker endomucin (1/100, Santa Cruz V7C7) and
AlexaFlour 546-conjugated secondary antibody and mounted in
Prolong Gold anti-fade reagent with DAPI (Invitrogen, Paisley,
UK). Stained sections were visualised on a Zeiss Axioplan micro-
scope, and blood vessel number and tumour section area system-
atically counted and measured for the whole section area. For
each xenograft, blood vessel density was calculated across a
midline tumour section using the formula (Σ number of blood
vessels)/(Σ section area). RNA was extracted using the manufac-
turer’s recommended protocol following homogenisation in
Tripure reagent.
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In vitro clonogenic and proliferation assays
A549 HRE wild-type and mutant cells were seeded into 6-cm plates
at 5 × 104 cells per plate. Twenty-four hours after seeding plates
were placed into 1% O2. Forty-eight hours postseeding, three plates
for each condition were trypsinised and counted using a TC20TM
BioRad Cell Counter. Each plate was counted in duplicate and an
average cell count calculated. Plates were counted 48, 72, 120 and
168 h postseeding, and growth curves generated. Four biological
repeats of this experiment were conducted.
Microarray analysis
RNA was extracted from HBEC treated for 72 h with 80 nM scrambled
or LIMD1 targeting siRNA in quadruplet. Microarray analysis was
performed by the Genome Centre, Bart’s Cancer Institute using a
HT12v4.0 Illumina array. Raw data were normalised and fold-change
gene expression calculated from the average expression value for each
condition. Genes with a q value cut-off of < 0.15 were analysed by
ingenuity pathway analysis (IPA) [Qiagen] software using fold-change
values for each mRNA: siRNA LIMD1 versus siRNA scrambled. Gene
ontology was collected from the Bio Functions read-out of IPA results
where activation was > +1 or < 1 (Dataset EV1), and categories were
collapsed into similar overall functions, e.g. apoptosis and cell
survival, and directionality of function was inferred from the activation
z-score in Dataset EV1. The HIF-1a transcription factor was indicated
as an activated upstream regulator by IPA (HBEC activation score
3.114 and P-value of overlap 1.76E-04); therefore, this was also repre-
sented in the heat map. These categories were then applied to the heat
map for functional clustering; only genes that were placed in these
enriched categories are shown. IPA upstream analysis also produced a
network of HIF-1a interactions for HBEC siRNA LIMD1 versus siRNA
scrambled treated. These interactions and the predicted activation
state of downstream effectors are inferred from the total gene set
submitted for IPA (q < 0.15).
Patient cohort and immunohistochemistry
The overall number of patients within the cohort was 276 of which
276 were valid for immunohistochemistry staining. The cohort
consisted of 150 males and 126 females with an age range of 36–
91 years. Ninety-three percentage of cases were adenocarcinoma,
3% small-cell carcinoma and 4% other types, and all 276 tumour
cores were of primary lung tumour origin. Informed consent was
obtained from all subjects, and the experiments conformed to the
principles set out in the WMA Declaration of Helsinki and the
Department of Health and Human Services Belmont Report. IHC
was carried out as previously described (Sharp et al, 2008;
Spendlove et al, 2008). Briefly, slides were heated to 60°C on a
hotplate (Leica, HI1220) for 10 min, allowed to cool for 5 min
before being dewaxed in a Leica autostainer. Antigen retrieval was
then performed via microwave for 20 min in citrate buffer pH 6.0
for VEGF sections. Antigen retrieval for LIMD1 was carried out in a
water bath Epitope retrieval solution 2 pH 9.0 (Bond) at 95°C for
35 min. Slides were peroxidase treated (Novolink) for 5 min in
Sequenza trays, washed with TBS twice for 5 min and blocked
(Novolink) for 5 min. The working dilutions of the antibodies were
then made up in antibody diluent (Bond leica); LIMD1 1/200, and
VEGF-A Pre-diluted (SP28, Abcam). Beta-2-microglobulin 1/2,000
(Dako, A0072) was used as a reference positive control, and nega-
tive controls were without primary antibody. Each antibody at its
chosen dilution was incubated for 60 min before being washed
(×2). Secondary and tertiary reagents (Novolink postprimary and
polymer) were incubated on the slides for 30 min each with a
washing step between. Slides were developed with DAB solution
(Novolink) and counterstained with haematoxylin (Novolink) for
6 min. Slides were then dehydrated and mounted in DPX prior to
observation and laser scanning.
Statistics
Statistical analyses were performed using R 3.4.4 and are described
in each figure legend. Where systematic differences existed between
experimental runs, data were analysed with mixed-model ANOVA
allowing a separate intercept and effect of time for each run.
Homoscedasticity and normality of all model residuals were evalu-
ated graphically. Where residuals were non-normal or heteroscedas-
tic, the model was refit to the log10-transformed dependent variable.
If model assumptions were still not met, nonparametric tests or
The paper explained
Problem
Within solid tumours, including lung cancer, inadequate oxygen levels
(hypoxia) create an environment that is a driving force of cancer
progression and form a resistance mechanism to all forms of therapy
such as standard chemotherapies and ionising radiation. In chronic
hypoxia, the transcriptional regulators of hypoxia (HIFs) are degraded
through negative feedback loops; however, neoplastic cells evade this
to survive in this harsh microenvironment. How this occurs in non-
small-cell lung cancer is poorly understood and serves as an area of
significant interest for cancer biology and potential hypoxia-based
targeted therapies.
Results
We identified that the tumour suppressor LIMD1, which facilitates
efficient degradation of the transcriptional regulator of hypoxia (Foxler
et al, 2012), is itself a HIF target gene. This creates a negative feed-
back loop whereby the activity of HIF is limited under prolonged
hypoxic exposure, and mitigates pro-tumorigenic effects of hypoxia.
Subcutaneous implantation of cells lacking this feedback mechanism
formed larger and more vasculature in vitro. Furthermore, in silico
analysis of TCGA data shows that LIMD1 is lost in 47% of lung adeno-
carcinoma and serves as an independent prognostic marker. Deeper
analysis of this dataset reveals a negative correlation between LIMD1
and a hypoxic gene set which further correlates with patient
outcome.
To conclude, we have identified a novel LIMD1-mediated negative
feedback loop of HIF regulation that effects tumour growth, highlight-
ing the functional importance of LIMD1 expression in normal lung
homeostasis and the tumorigenic advantage its loss/deregulation
gives to the hypoxic tumour microenvironment.
Impact
Our findings open a new field of research into the aetiology, diagnosis
and prognosis of LIMD1-negative lung cancers and hold the potential
for advances in the stratification of patients with respect to deregu-
lated HIF regulation and associated phenotypes. This holds the poten-
tial for development of chemotherapeutic drugs that target LIMD1 loss
which could be used in combination with hypoxia-targeted therapies.
ª 2018 The Authors EMBO Molecular Medicine e8304 | 2018 15 of 18
Daniel E Foxler et al HIF–LIMD1 negative feedback mechanism EMBO Molecular Medicine
Published online: June 21, 2018 
Welch-corrected Student’s t-tests were used instead. Where data are
normalised to a group, this group was excluded from the analysis.
One-sample Student’s t-tests were used when comparing data to a
standardised group (theoretical value of 1).
Data availability
Microarray data from this publication have been deposited to Gene
Expression Omnibus and assigned the identifier accession number
GSE114692.
Expanded View for this article is available online.
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